相关实验视频

Updated: Jun 6, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

改变EGFR突变非小细胞肺癌的治疗环境

Fei Zhou¹, Haoyue Guo¹, Yang Xia²

¹Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

Nature reviews. Clinical oncology

|November 29, 2024

概括

第三代EGFRTKI是EGFR突变非小细胞肺癌 (NSCLC) 的标准. 研究探索组合和新的治疗方法,以克服耐药性和改善NSCLC患者的存活率.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
EGFR氨酸激酶抑制剂 (TKIs) 已经改变了NSCLC的治疗方法,第三代TKIs是目前先进EGFR突变NSCLC的第一线标准.
中枢神经系统 (CNS) 透是第三代EGFR TKI的一个显著特征.

研究的目的:

审查目前EGFR突变NSCLC的第一线治疗策略.
阐明获得对第三代EGFR技术知识的耐药性机制.
探索用于管理EGFR突变NSCLC的新和有前途的治疗方法,包括耐药性设置.

主要方法:

对EGFR突变性NSCLC的现有和新兴治疗方法的综合文献综述.
对第三代EGFR技术技能耐药性机制的分析.
探索合理的药物组合和新的治疗方式.

主要成果:

第三代EGFRTKI是先进EGFR突变NSCLC的标准一线治疗方法.
结合策略 (例如,与抗血管性药物,化疗,阿米万塔马布) 和早期TKI使用正在调查中.
新兴的治疗方法,如新的TKI,抗体-药物合物,免疫疗法和向蛋白质降解剂,对获得的耐药性有很大的承诺.

结论:

优化一线治疗和开发克服获得性耐药性的策略对于改善EGFR突变NSCLC的结果至关重要.
研究新组合和治疗剂对于解决治疗挑战和提高患者存活率至关重要.
未来的研究应该专注于创新的方法,以实现长期的疾病控制和治疗EGFR突变的NSCLC患者的潜在疗法.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.